Gene Therapy Is Entering Its Durability Audit Era
The latest update from Taysha Gene Therapies is easy to misread as a conventional rare-disease data release. The company announced…
Author: Jane Aubrey
Jane Aubrey brings over a decade of experience as a clinical researcher to her reporting on drug development and regulatory pathways. At The Biotech Codex, she breaks down complex trial data and analyzes the pipeline strategies of both emerging biotechs and legacy pharma giants. Her coverage demystifies the arduous journey from bench to bedside, keeping industry professionals informed on the latest therapeutic breakthroughs.
Drug Pricing Is Becoming Trade Policy
Biotech investors are used to thinking about drug pricing as a domestic argument. The traditional battle lines are familiar: governments…
Biotech Patents Are Becoming Industrial Policy Again
Biotech investors usually discuss competitiveness in terms of research quality, clinical execution, manufacturing depth, or access to capital. Those still…
The Obesity Boom Is Becoming a Distribution Crackdown
The latest FDA warning-letter wave shows that the next fight in GLP-1 medicine is shifting from molecule scarcity to control…
Oncology’s New Bottleneck Is Becoming Treatment Matching
As therapies become more complex and more expensive, biotech is discovering that the next moat may lie in predicting response…
Biotech’s Market Is Open Again, but Only for the Most Credible Stories
The current biotech tape is not broadly forgiving. It is rewarding scalable platforms, manufacturing leverage, and differentiated clinical assets while…
The Personalized Vaccine Revolution: mRNA Rewrites the Rules of Cancer Immunotherapy
Five-year melanoma data and early breakthroughs in pancreatic and brain cancers signal that individualized mRNA vaccines are maturing from proof…
The Liquid Biopsy Reality Check: Navigating the Promise and Limits of Blood-Based Cancer Detection
As multi-cancer early detection tests generate immense excitement, oncologists emphasize the need for rigorous clinical validation and temper expectations regarding…
Beyond the Short Read: How Long-Read Sequencing is Solving the Unsolvable
A landmark study demonstrates that long-read genome sequencing can replace 15 separate diagnostics for rare genetic diseases, while also illuminating…
A Milestone in Gene Therapy: Restoring Sound and the Base Editing Debate
The FDA’s landmark approval of an in vivo gene therapy for hearing loss signals a new era for biotechnology, even…
The Unraveling of the Managed Care Model: How UnitedHealth’s Crisis is Reshaping the Insurance Landscape
As federal investigations, state lawsuits, and bipartisan pushback against AI-driven prior authorization converge, the health insurance industry faces a profound…